Autres langues Lipella Pharmaceuticals Inc.

Actions

LIPO

US53630L1008

Temps réel estimé Cboe BZX Autres places de cotation 15:37:56 17/05/2024			Varia. 5j.	Varia. 1 janv.
0,77 ^USD	+0,99%		+1,65%	-25,25%

09/05	Lipella Pharmaceuticals Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
17/04	Lipella Pharmaceuticals Inc. nomme Jason Hafron et Pradeep Tyagi au conseil scientifique consultatif	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise	17/04
Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board	17/04
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024	05/04
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis	03/04
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease	07/03
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline	05/03
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline	05/03
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference	20/02
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished	20/12
Wall Street Set to Open Lower Friday; Employment Growth Tops Forecasts	08/12
Top Premarket Decliners	08/12
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Lipella Gets FDA Orphan Designation for LP-310 in Oral Graft-vs-Host Disease	10/11
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease	10/11
Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules	25/10/23
Lipella Pharmaceuticals Inc. announced that it has received $1.998685 million in funding	25/10/23
Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules	24/10/23
Lipella Pharmaceuticals Inc. announced that it expects to receive $1.998685 million in funding	24/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lipella Pharmaceuticals Inc.

Actions

LIPO

US53630L1008

Autres langues

Filtres